[Hepatorenal syndrome: diagnosis, treatment and prevention]

Ugeskr Laeger. 2013 May 27;175(22):1562-6.
[Article in Danish]

Abstract

Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based interventions in HRS. A number of factors can precipitate HRS. The monitoring, prevention, early detection, and correct treatment of these are essential. Terlipressin combined with albumin is the first-line treatment of type 1 HRS. In type 2 HRS with refractory ascites, liver transplantation and TIPS should be considered.

Publication types

  • Review

MeSH terms

  • Albumins / therapeutic use
  • Ascites / diagnosis
  • Ascites / etiology
  • Ascites / prevention & control
  • Ascites / therapy
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Hepatorenal Syndrome* / diagnosis
  • Hepatorenal Syndrome* / etiology
  • Hepatorenal Syndrome* / prevention & control
  • Hepatorenal Syndrome* / therapy
  • Humans
  • Kidney / drug effects
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / therapy
  • Liver Transplantation
  • Lypressin / adverse effects
  • Lypressin / analogs & derivatives
  • Lypressin / therapeutic use
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Terlipressin
  • Vasoconstrictor Agents / adverse effects
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Albumins
  • Vasoconstrictor Agents
  • Lypressin
  • Terlipressin